Published in J Clin Pharmacol on July 11, 2014
First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium. Cancer Chemother Pharmacol (2016) 0.75
Unveiling changes in the landscape of patient populations in cancer early drug development. Oncotarget (2016) 0.75
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol (2005) 7.12
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol (2011) 3.00
Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer (2011) 2.38
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res (2010) 2.31
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res (2011) 1.20
QTL analysis for yield components and kernel-related traits in maize across multi-environments. Theor Appl Genet (2011) 1.11
Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology (2011) 0.93
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol (2010) 0.93
Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. Drug Metab Dispos (2010) 0.90
Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416. Toxicol In Vitro (2006) 0.88
Effects of the Des-F(6)-quinolone garenoxacin (BMS-284756), in comparison to those of ciprofloxacin and ofloxacin, on joint cartilage in immature rats. Antimicrob Agents Chemother (2002) 0.87
Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer. Prostate (2014) 0.85
Effect of a high-fat meal on the pharmacokinetics of the des-F(6)-quinolone BMS-284756. Pharmacotherapy (2002) 0.84
Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug. Pharm Res (2011) 0.84
Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects. Xenobiotica (2014) 0.84
Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother (2004) 0.82
Downregulation of miR-145 contributes to lung adenocarcinoma cell growth to form brain metastases. Oncol Rep (2013) 0.82
Pharmacokinetics and pharmacodynamics of figitumumab, a monoclonal antibody targeting the insulin-like growth factor 1 receptor, in healthy participants. J Clin Pharmacol (2013) 0.81
Pharmacokinetics, safety, and tolerability following multiple oral doses of varenicline under various titration schedules in elderly nonsmokers. J Clin Pharmacol (2010) 0.81
Correlations and comparisons of quantitative trait loci with family per se and testcross performance for grain yield and related traits in maize. Theor Appl Genet (2012) 0.81
The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers. J Acquir Immune Defic Syndr (2014) 0.80
Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin (2004) 0.80
Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study. J Clin Pharmacol (2007) 0.79
Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Res Treat (2008) 0.78
Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats. Arch Toxicol (2003) 0.78
Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk (2013) 0.78
The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers. Cancer Chemother Pharmacol (2011) 0.78
Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers. Curr Med Res Opin (2004) 0.77
No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects. Antimicrob Agents Chemother (2012) 0.77
Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies. EJNMMI Res (2012) 0.76
Dosing celecoxib in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol (2011) 0.76
The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies. Mol Cancer Ther (2011) 0.75
[ESTABLISHMENT OF INTERVERTEBRAL DISC DEGENERATION OF RABBITS BY USING MINIMALLY INVASIVE ACUPUNCTURE AND ROTARY-CUTTING]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2016) 0.75
Characterization of the penetration of garenoxacin into the breast milk of lactating women. J Clin Pharmacol (2004) 0.75
Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. Clin Pharmacokinet (2002) 0.75
Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib. Invest New Drugs (2015) 0.75